Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.

Pfizer vs Moderna battle over COVID vaccine patents begins in UK

CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil (Ministério da Saúde) to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19. This contract follows the Brazilian Health Regulatory Agency's (ANVISA) approval of Moderna's COVID-19 vaccine in March 2024, which encodes the spike protein of the XBB.1.5 sublineage of SARS-CoV-2 for active immunization for the prevention of COVID-19 in children from six months of age and adults.

Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.

Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

Medtronic

AI could solve one of the biggest problems in drug development: the lengthy time it takes to bring a product to market. The AI in healthcare market is set to expand at a compound annual growth rate of nearly 50%.

2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential

Intellia Therapeutics

Intellia is moving closer and closer to the finish line with two gene-editing candidates. Moderna's future looks bright again with new products on the way.

2 Stocks Down 30% to Buy Right Now

Merck

Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.

1 New Green Flag for Moderna and Merck Stock

LOS ANGELES--(BUSINESS WIRE)-- #Africa--AIDS Healthcare Foundation (AHF) says Moderna's promise to build a state-of-the-art mRNA manufacturing facility in Africa in 2022 was nothing more than a self-serving effort to deflect criticism for price gouging on its COVID-19 vaccine after the pharma company announced today that it's suspending the project. “Moderna's greed knows no bounds. It raked in $30 billion in profit since 2021. Now, it claims the mRNA factory in Kenya is no longer worth the investment be.

Moderna Betrays Africa, Says AHF

Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.

Moderna (MRNA) Stock Dips While Market Gains: Key Facts

ACADIA Pharma

Royalty Pharma

There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.

3 Pharma Stocks to Sell in April Before They Crash & Burn

Bristol-Myers

Viking Therapeutics

Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in value over the past six months, outpacing broader market gains.

If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names

Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint.

Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges

Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines.

Moderna puts Kenya plant plans on hold as COVID vaccine demand slumps

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?

Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated with its experimental individualized MRNA cancer vaccine combined with Merck's (MRK) blockbuster drug Keytruda.

Moderna Reports Positive Results from Cancer Vaccine-Keytruda Combination Trial

Moderna Inc.'s stock jumped 6% Tuesday to lead S&P 500 gainers, after the company shared cancer-vaccine data that suggests it may work in indications outside its target of melanoma.

Moderna's stock jumps 6% as its cancer vaccine could treat more than just melanoma

Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.

What made Moderna stock pop 10% on Tuesday?

Moderna shares rose 8% in morning trade on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer.

Moderna jumps as personalized cancer vaccine shows benefit in early study

Vertex Pharmaceuticals

Eli Lilly wowed patients and investors with its top-performing weight loss drugs. The big pharma company's stock has climbed in the triple digits over the past year thanks to its revenue growth.

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

iBio

Innovage Holding Corp

The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.

3 Healthcare Stocks Short Sellers Are Prescribing for Trouble

With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one's buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.

The 3 Most Undervalued Biotech Stocks to Buy in April 2024

Moderna stock rose after the company said its next-generation Covid shot beat out the original. Is MRNA stock a buy or a sell right now?

Is Moderna Stock A Buy As The Company Eyes The Covid Vaccine Market — Again?

Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.

Moderna shares fall after judge sides with Arbutus in patent fight

Moderna had a challenging 2023 as demand for its COVID-19 vaccines declined, but it still expects reasonable revenue in 2024. The company has a strong pipeline of products, including respiratory vaccines and potential joint flu/COVID-19 vaccines. Moderna's financial picture remains volatile, but it has a strong cash position and is investing heavily in R&D to build new businesses.

News for Moderna Stock (MRNA)